• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Testing

SARS-CoV-2 and Air Contamination in Hospitals

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Birgand et al. (JAMA Network Open, 2020) reviewed current evidence on SARS-CoV-2 air contamination in different hospital areas

METHODS:

  • Review and meta-analysis
  • Data sources
    • MEDLINE | Embase | Web of Science databases (between January 1 and October 27, 2020)
  • Inclusion criteria
    • Articles detailing SARS-CoV-2 air contamination in hospital settings
  • Study design
    • Positivity rate of SARS-CoV-2 viral RNA and culture were calculated based on setting, clinical context, air ventilation system, and distance from patients
    • SARS-CoV-2 RNA concentrations in copies per meter cubed of air were pooled distribution analyzed by hospital areas
    • Particle sizes and SARS-CoV-2 RNA concentrations in copies or median tissue culture infectious dose (TCID50) per meter cubed were analyzed with categorization (aerosol particles <5 μm in diameter) 
      • <1 μm
      • From 1 to 4 μm
      • >4 μm

RESULTS:

  • 24 cross-sectional observational studies | 471 air samples
  • Air samples from close patient environments: 17.4% positive for SARS-CoV-2 RNA
  • There was a significantly higher positive rate in ICU settings (P < 0.001)
    • ICU air samples: 25.2% positive
    • Non-ICU air samples: 10.7% positive
  • There was no difference in air sample positivity rate according to the distance from patients (P = 0.22)
    • ≤1 m: 2.5% positive
    • >1 to 5 m: 5.5% positive
  • Air sample positivity rate based on hospital area
    • Toilets: 23.8% positive
    • Clinical areas: 12.3% positive
    • Public areas: 33.3% positive
  • Viral cultures performed: 5 studies | 81 total viral cultures
    • 8.6% of air samples from only 2 studies were positive | All from close patient environments (non-ICU rooms)
  • Median (IQR) SARS-CoV-2 RNA concentrations varied based on location
    • Clinical areas: 1.0 × 103 copies/m3 (0.4 × 103 to 3.1 × 103 copies/m3)
    • Toilets: 9.7 × 103 copies/m3 (5.1 × 103 to 14.3 × 103 copies/m3)
  • Protective equipment removal and patient rooms had high concentrations per titer of SARS-CoV-2
    • Concentration range: 0.9 × 103 to 40 × 103 copies/m3 
    • Tissue culture range: 3.8 × 103 to 7.2 × 103 TCID50/m3
  • Particle sizes peaks
    • Protective equipment removal and patient rooms: <1 μm
    • Staff offices: >4 μm

CONCLUSION:

  • There was widespread contamination of hospital areas with SARS-CoV-2 RNA, but these air samples rarely contained infectious virus
  • Severity of infections were not associated with increased air contamination
  • There was a particularly high viral load in toilets and bathrooms, staff areas, and public hallways
  • Authors note limitations, including lack of detail in studies used for the analysis
  • The authors conclude

High viral loads found in toilets and/or bathrooms, staff areas, and public hallways argue for a careful consideration of these areas for the prevention of COVID-19 transmission

However, the presence of viable viruses should be primarily considered, given that it is a required link for the potential of cross-transmission 

Learn More – Primary Sources:

Assessment of Air Contamination by SARS-CoV-2 in Hospital Settings

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Testing Posts
Next >

Related ObG Topics:

Aerosols and Surfaces: SARS-CoV-2 Stability
Surgical Masks Reduce Viral Shedding
Universal Masking and COVID-19 Infection Rates in Healthcare Personnel
What is the SARS-CoV-2 Transmission Risk Associated with Prenatal Visits?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site